0001181431-14-005721.txt : 20140207 0001181431-14-005721.hdr.sgml : 20140207 20140207134506 ACCESSION NUMBER: 0001181431-14-005721 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140205 FILED AS OF DATE: 20140207 DATE AS OF CHANGE: 20140207 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hora Maninder CENTRAL INDEX KEY: 0001443159 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 14583418 MAIL ADDRESS: STREET 1: PDL BIOPHARMA, INC. STREET 2: 1400 SEAPORT BOULEVARD CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 rrd401715.xml ANNUAL EQUITY COMPENSATION X0306 4 2014-02-05 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001443159 Hora Maninder 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 0 1 0 0 SVP Pharma Dev and Mfg Stock Option 12.43 2014-02-05 4 A 0 50000 0 A 2022-02-04 Common Stock 50000 50000 D Stock Option 12.43 2014-02-05 5 A 0 50000 0 A 2022-02-04 Common Stock 50000 50000 D This option was granted on February 5, 2014 and vests in monthly installments over the four-year period following the grant date. This stock option is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the shares subject to the option become vested and exerciseable. The time-based vesting is on a monthly pro-rata basis over a period of four (4) years from the grant date (February 5, 2014). The performance-based vesting condition will be met only if Nektar (or a licensee) files, within five years following the grant date, a new drug registration with the FDA or the European Medicines Agency for a significant drug candidate program (avg. royalty >7.5%) including, without limitation, the following: (1) etirinotecan pegol; (2) NKTR-061/Amikacin Inhale; (3) BAX-855 (a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein; or (4) dry powder inhaled ciprofloxacin. Gil M. Labrucherie, Attorney-in-Fact 2014-02-07